GlassScriptPhysician profile
Bolos Gerges
NPI 1053016105
$606.78
in general payments reported to CMS, 2019-2025
9 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $389 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $223.41 | 2024-2025 | Prolia, Evenity, Repatha |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2024 | Opdivo |
| Lexicon Pharmaceuticals, INC. | $113.32 | 2024 | Inpefa |
| Janssen Biotech, INC. | $41.35 | 2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $32.08 | 2025 | |
| United Therapeutics Corporation | $21.24 | 2024 | Tyvaso |
| Vertex Pharmaceuticals Incorporated | $18.03 | 2024 | |
| Pfizer INC. | $16.55 | 2025 | |
| Mallinckrodt Hospital Products INC. | $15.80 | 2024 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bolos Gerges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.